Cargando…

Prescribing cannabis for harm reduction

Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal pois...

Descripción completa

Detalles Bibliográficos
Autor principal: Collen, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295721/
https://www.ncbi.nlm.nih.gov/pubmed/22208773
http://dx.doi.org/10.1186/1477-7517-9-1
_version_ 1782225628126248960
author Collen, Mark
author_facet Collen, Mark
author_sort Collen, Mark
collection PubMed
description Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications.
format Online
Article
Text
id pubmed-3295721
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32957212012-03-07 Prescribing cannabis for harm reduction Collen, Mark Harm Reduct J Commentary Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications. BioMed Central 2012-01-01 /pmc/articles/PMC3295721/ /pubmed/22208773 http://dx.doi.org/10.1186/1477-7517-9-1 Text en Copyright ©2012 Collen; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Collen, Mark
Prescribing cannabis for harm reduction
title Prescribing cannabis for harm reduction
title_full Prescribing cannabis for harm reduction
title_fullStr Prescribing cannabis for harm reduction
title_full_unstemmed Prescribing cannabis for harm reduction
title_short Prescribing cannabis for harm reduction
title_sort prescribing cannabis for harm reduction
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295721/
https://www.ncbi.nlm.nih.gov/pubmed/22208773
http://dx.doi.org/10.1186/1477-7517-9-1
work_keys_str_mv AT collenmark prescribingcannabisforharmreduction